Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in AustraliaGlobeNewsWire • 10/03/22
Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19GlobeNewsWire • 09/13/22
Altamira Therapeutics to Participate in the 4th Annual RAS-Targeted Drug Development SummitGlobeNewsWire • 09/08/22
Altamira Therapeutics' CEO Interviewed by Proactive Investors to Discuss its Pipeline of RNA Therapeutics and Ongoing Strategic TransformationGlobeNewsWire • 08/03/22
Altamira Therapeutics Completes Interim Sample Size Analysis of COVAMID Trial with Bentrio in Acute COVID-19GlobeNewsWire • 08/01/22
Altamira Therapeutics' Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed JournalGlobeNewsWire • 07/28/22
Altamira Therapeutics to Develop Novel Generation of Rheumatoid Arthritis Therapeutics Based on its Proprietary OligoPhore Delivery Platform and siRNA Targeting Key Inflammation CheckpointGlobeNewsWire • 07/25/22
Altamira Therapeutic's SemaPhore Platform Shown Particularly Effective in Intracellular mRNA Delivery for Cancer TherapyGlobeNewsWire • 07/19/22
Altamira Therapeutic's RNA Delivery Platform Shown to be an Effective Treatment for Abdominal Aortic Aneurysm as Published in Peer-Reviewed JournalAccesswire • 07/12/22
Altamira Therapeutics Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and PakistanAccesswire • 06/29/22
Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic RhinitisAccesswire • 06/27/22
Altamira Therapeutics Achieves COVAMID Trial Target Enrollment for Bentrio in Acute COVID-19Accesswire • 06/23/22
Altamira Therapeutics Announces Top-Line Data from AM-125 Phase 2 Study in Acute VertigoAccesswire • 06/13/22
Altamira Therapeutics Receives NASDAQ Notification Regarding Minimum Bid RequirementsAccesswire • 06/09/22
Altamira Therapeutics Reports 89.5% and 98.9% Reduction in Viral Load Against Human Rhinovirus With its Bentrio Nasal SprayAccesswire • 06/08/22
Altamira Therapeutics Announces Marketing Approval for Bentrio Nasal Spray in IndonesiaAccesswire • 05/31/22
Altamira Therapeutics Announces Positive Top-line Results from its Clinical Trial with Bentrio Nasal Spray in House Dust Mite StudyAccesswire • 05/20/22
Altamira Therapeutics to Present at the 2022 H.C. Wainwright Global Investment ConferenceAccesswire • 05/19/22